The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
26-Nov-07
$11.4 billion
Target:
Kelda Group plc
Acquiror:
Citi Infrastructure Investors, GIC Special Investments, Infracapital Partners and HSBC Bank
Advised Kelda Group plc, a leading provider of water and waste water services in the UK, on a recommended cash offer from a consortium of international infrastructure investors
31-Jul-08
$10.3 billion
Target:
TransAlta Corporation
Acquiror:
LS Power Equity Partners / Global Infrastructure Partners
Advised TransAlta Corporation, a power generation and wholesale marketing company, on an unsolicited offer from LS Power Equity Partners / Global Infrastructure Partners
07-Jun-09
$1.6 billion
Target:
EPCOR Power L.P.
Advised the Independent Committee of the Board of Directors of EPCOR Power L.P., an Alberta-based power trust, on approval of the transfer of its GP interest and 30.6% LP interest from EPCOR Utilities to a newly formed company, Capital Power Corporation
30-Jun-10
$820 million
Target:
Trident Resources Corporation
Advised Chilton Investment Company on Trident’s financial restructuring and emergence from CCAA / Chapter 11 bankruptcy protection including the negotiation of a new equity investment
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
20-Jun-11
$2.0 billion
Target:
Capital Power Income L.P.
Acquiror:
Atlantic Power Corporation
Advised Capital Power Income L.P., a Canadian power trust with a portfolio of 20 power generation assets located in Canada and the United States (total net generating capacity of 1,400 MW), on its sale to Atlantic Power Corporation
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
08-Jun-15
$45 million
Target:
Aralez Pharmaceuticals Inc.
Acquiror:
QLT Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
14-Jun-15
$912 million
Target:
Niska Gas Storage Partners
Acquiror:
Brookfield Infrastructure Group
Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
20-Aug-15
$1.0 billion
Target:
COOEC Fluor Heavy Industries Co., Ltd.
Acquiror:
Fluor Corporation
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
26-Apr-18
$NA
Target:
IslaLink
Acquiror:
Fiera Infrastructure
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
29-May-18
$3.5 billion
Target:
Trans Mountain Pipeline system, Trans Mountain Expansion Project and related pipeline and terminal assets
Acquiror:
Government of Canada
Advised the Government of Canada on the acquisition of the Trans Mountain Pipeline system, the Trans Mountain Expansion Project and related pipeline and terminal assets from Kinder Morgan Canada Limited
28-Jun-18
$146 million
Target:
35% of Sabine Oil & Gas’ interest in oil and gas properties in East Texas
Acquiror:
Osaka Gas
Advised Osaka Gas, a Japanese utility, on the acquisition of 35% of Sabine Oil & Gas’s interest in oil and gas properties located primarily in Harrison and Panola Counties, Texas
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited